Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00946920 · ClinicalTrials.gov registry record · Phase 3
A Trial of Degarelix in Patients With Prostate Cancer
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 859
- Enrollment target
NCT00946920 is a Phase 3 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 859 participants.
The verdict
NCT00946920, a Phase 3 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 859 participants
- Enrollment target
Study Summary
A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in patients with prostate cancer.
Interventions
- DRUG Degarelix
- DRUG Goserelin acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 859 participants |
| Start Date | 2009-06 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00946920
The ClinicalTrials.gov registry entry for NCT00946920 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 859 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Degarelix is the first listed.
NCT00946920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00946920 about?
NCT00946920 is a clinical study titled "A Trial of Degarelix in Patients With Prostate Cancer". A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in patients with prostate cancer.
What is the current status of trial NCT00946920?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 859 participants. The study started on 2009-06. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00946920?
The interventions under investigation include: Degarelix (DRUG), Goserelin acetate (DRUG).
Who is sponsoring clinical trial NCT00946920?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.